Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS OTCMKTS:ARGSQ OTCMKTS:CPMD NASDAQ:PBM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.05$0.07$0.02▼$0.78$2.26M1.174,709 shs18 shsARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ACPMDGolden Dragon$0.00-6.3%$0.00$0.00▼$0.01$1.98M2.12107,968 shs20,000 shsPBMPsyence Biomedical$3.24+1.3%$5.07$2.36▼$319.20$6.05M0.224.99 million shs77,440 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-1.12%+52.74%+51.86%+158.54%ARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%CPMDGolden Dragon0.00%-6.25%+3.45%-38.78%-68.42%PBMPsyence Biomedical0.00%-0.92%-67.57%-26.20%-98.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARGSQArgos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACPMDGolden DragonN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence Biomedical1.168 of 5 stars0.05.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AARGSQArgos Therapeutics 0.00N/AN/AN/ACPMDGolden Dragon 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.70N/AN/A($2.06) per share-0.03ARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03CPMDGolden Dragon$820K2.42N/AN/A($0.04) per share-0.08PBMPsyence BiomedicalN/AN/A$1.79 per share1.81$11.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AARGSQArgos Therapeutics-$40.57MN/A0.00∞N/AN/AN/AN/AN/ACPMDGolden Dragon-$9.91M-$0.01N/A∞N/A-423.36%N/A-34.17%N/APBMPsyence Biomedical$1.01MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AARGSQArgos TherapeuticsN/AN/AN/AN/AN/ACPMDGolden DragonN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AARGSQArgos TherapeuticsN/AN/AN/ACPMDGolden DragonN/A0.040.01PBMPsyence BiomedicalN/A11.0411.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ARGSQArgos TherapeuticsN/ACPMDGolden DragonN/APBMPsyence Biomedical77.44%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ARGSQArgos Therapeutics28.21%CPMDGolden Dragon1.27%PBMPsyence Biomedical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableCPMDGolden Dragon4660.63 million652.24 millionNot OptionablePBMPsyence BiomedicalN/A1.87 million1.80 millionN/AARGSQ, PBM, ADXS, and CPMD HeadlinesRecent News About These CompaniesPsyence Biomedical Ltd. (PBM) Stock Price Today - WSJAugust 5, 2025 | wsj.comPacific Bay Warrant Extension Not ProceedingAugust 1, 2025 | newsfilecorp.comNPsyence Biomedical stock soars after partner achieves ibogaine breakthroughAugust 1, 2025 | za.investing.comPsyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction BreakthroughAugust 1, 2025 | msn.comPsyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | financialpost.comFPsyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | globenewswire.comPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesJune 18, 2025 | globenewswire.comPsyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025June 18, 2025 | newsfilecorp.comNPsyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | finanznachrichten.dePsyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | newsfilecorp.comNCVS Sues Arkansas Over Law Banning PBM Ownership Of PharmaciesMay 29, 2025 | forbes.comPsyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialMay 27, 2025 | newsfilecorp.comNPsyence Biomedical Ltd. WtMay 21, 2025 | marketwatch.comPsyence Biomedical Advances Psilocybin Drug Development as of May 2025May 20, 2025 | tipranks.comPsyence Biomedical announces reverse stock splitMay 2, 2025 | investing.comPsyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock SplitMay 1, 2025 | newsfilecorp.comNPsyence Group consolidates its sharesApril 18, 2025 | greenmarketreport.comGPsyence BioMed gets Nasdaq notice for non-complianceApril 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARGSQ, PBM, ADXS, and CPMD Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.05 0.00 (0.00%) As of 08/22/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Argos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Golden Dragon OTCMKTS:CPMD$0.0030 0.00 (-6.25%) As of 08/22/2025 02:33 PM EasternCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.Psyence Biomedical NASDAQ:PBM$3.24 +0.04 (+1.25%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.24 +0.00 (+0.15%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access